ArticleOncoTargets and therapy2018
Association between IL-17A G197A polymorphism and gastric cancer risk: an updated meta-analysis based on 6,624 cases and 7,631 controls.
Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Genetic polymorphisms of IL-17A rs2275913, rs3748067 and IL-17F rs763780 in gastric cancer risk: evidence from 8124 cases and 9873 controls.Molecular biology reports · 2018Pooled it
- Immunological Aspects of the Tumor Microenvironment and Epithelial-Mesenchymal Transition in Gastric Carcinogenesis.International journal of molecular sciences · 2020Review
- Genetic polymorphisms and gastric cancer risk: a comprehensive review synopsis from meta-analysis and genome-wide association studies.Cancer biology & medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePrevious studies investigating the association between interleukin-17A (IL-17A) G197A polymorphism and gastric cancer risk have provided inconsistent results. We, therefore, conducted this meta-analysis to clarify the association between IL-17A G197A polymorphism and gastric cancer risk.
methodsWe searched PubMed, Excerpta Medica Database, and CNKI databases to identify relevant studies up to June 10, 2017. A total of 16 case-control studies including 6,624 cases and 7,631 controls were identified.
resultsOverall, significant associations between IL-17A G197A polymorphism and gastric cancer risk were observed (A vs G: OR =1.24, 95% CI =1.14-1.36; AA vs GG: OR =1.63, 95% CI =1.35-1.96; GA vs GG: OR =1.12, 95% CI =1.01-1.25; AA+GA vs GG: OR =1.23, 95% CI =1.11-1.35; AA vs GA+GG: OR =1.54, 95% CI =1.27-1.87). Similar associations were also observed in Asian population (A vs G: OR =1.25, 95% CI =1.15-1.37; AA vs GG: OR =1.62, 95% CI =1.33-1.97; GA vs GG: OR =1.16, 95% CI =1.07-1.25; AA+GA vs GG: OR =1.24, 95% CI =1.15-1.33; AA vs GA+GG: OR =1.51, 95% CI =1.23-1.85), in Caucasian population (AA vs GA+GG: OR =2.19, 95% CI =1.40-3.44), and in the hospital-based controls' subgroup (A vs G: OR =1.30, 95% CI =1.17-1.45; AA vs GG: OR =1.81, 95% CI =1.46-2.25; AA+GA vs GG: OR =1.27, 95% CI =1.12-1.43; AA vs GA+GG: OR =1.71, 95% CI =1.34-2.18).
conclusionsThe current meta-analysis suggests that IL-17A G197A polymorphism might enhance gastric cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.